The purpose of this study is to look at how safe the vaccine is and to measure how well it helps the body’s defense system respond to different versions of the virus. People taking part in this study will be adults aged 65 or older who have already received their initial COVID-19 vaccination series and at least one additional booster dose, with their last dose given at least six months before joining the study. During the study, participants will receive one dose of the vaccine and will be checked for any side effects that might occur within the first week after vaccination, as well as any other health issues that might happen throughout the entire study period.

The study will also measure the level of antibodies in the blood, which are proteins that help fight off infections. These measurements will be taken before receiving the vaccine and again 14 days after vaccination to see how much the body’s immune response has increased. The antibodies will be tested specifically against the Omicron variant and other versions of the virus that are currently important in terms of public health. This information will help researchers understand how well the vaccine prepares the body to fight off these different virus variants.

The purpose of the study is to find out if adding Privigen to standard care helps patients recover from COVID-19 better than standard care alone. The study will specifically look at whether patients recover clinically and whether the virus is cleared from their blood by day 28 after joining the study. Patients in this study will have had COVID-19 symptoms for at least 7 days, will have received full COVID-19 vaccination, and will have the virus present in their blood. They will also have very low levels of antibodies against the virus due to their weakened immune system caused by their disease or treatment.

During the study, patients will be randomly assigned to receive either Privigen added to their standard care or standard care alone. The study will track how well patients are doing using a scale that measures their clinical condition, and will check whether the virus can still be found in their blood at different time points. The study will follow patients for several months to see if they maintain their recovery and to monitor for any side effects or safety concerns related to the treatments.

The purpose of this study is to find out how well the vaccine works in reducing the risk of COVID-19 that requires medical attention compared to not receiving the vaccine. The study will also look at how safe the vaccine is in this age group. This is a randomized trial, which means that participants will be assigned by chance to either receive the vaccine or not receive it. The researchers will then compare the two groups to see if there are differences in how many people develop COVID-19 that needs medical care.

During the study, researchers will track whether participants develop COVID-19 by looking at positive test results or hospital admissions related to the infection. They will also look at other outcomes such as hospitalizations for breathing problems related to COVID-19, heart and breathing problems, and deaths. The study will follow participants over time to collect this information and determine how effective the vaccine is in preventing illness in this specific age group without other health conditions that put them at higher risk.

During the study, participants will take multiple doses of nirmatrelvir/ritonavir. After these doses, a single oral dose of rosuvastatin will be administered. Researchers will then monitor the pharmacokinetics, which refers to how a drug moves through the body, including how it is absorbed, distributed, and eliminated. This process is measured by looking at the concentration of the medicine in the blood over time.

The purpose of this study is to find out if trimodulin is effective and safe when added to standard care for treating hospitalized adult patients with community-acquired pneumonia or COVID-19 pneumonia. The study will look at whether patients who receive trimodulin do better than those who receive placebo by measuring how many patients get worse or die during the study period. Patients in the study will receive the treatment through an infusion into a vein over five days.

During the study, doctors will monitor patients for up to 91 days to see how they respond to treatment. They will check if patients need more intensive breathing support or if their condition improves, stays the same, or gets worse. The study will also measure various blood markers related to inflammation, immune system function, and blood clotting to understand how the treatment works in the body. Safety will be carefully watched by recording any unwanted effects that occur during and after the treatment period.

People taking part in this study must have tested positive for the virus that causes COVID-19 within four days before joining and must have symptoms like cough, sore throat, fever, muscle aches, or other common signs of the infection. They also need to have certain health conditions or characteristics that put them at higher risk for severe illness, such as being 75 years or older, having a weakened immune system, or having multiple health problems like diabetes or lung disease. Additionally, participants must be unable or unwilling to take another COVID-19 treatment called nirmatrelvir with ritonavir for various reasons, such as taking other medicines that would interact badly with it or having certain liver problems.

During the study, participants will take either molnupiravir or placebo tablets for five days, with a maximum daily dose of 1600 milligrams. The study will track whether participants need to go to the hospital, experience death, or need medical care related to COVID-19 over a period of 29 days. The study will also monitor how quickly symptoms improve, measure the amount of virus in the body over time, and watch for any unwanted side effects that occur during treatment. This information will help researchers understand whether molnupiravir is helpful and safe for people with COVID-19 who are at high risk for serious illness.

The purpose of this research is to evaluate how well remdesivir works in protecting kidney transplant patients from developing severe COVID-19 after their transplant surgery. These patients are particularly vulnerable to complications from COVID-19 because their immune system needs to be suppressed to prevent organ rejection. The medication will be given to patients who have received at least three COVID-19 vaccine doses and have tested positive for the virus within 5 days before their scheduled kidney transplant.

During the study, patients will receive remdesivir through an intravenous line for 10 days. The total amount of medication will not exceed 1100 mg, with a maximum daily dose of 200 mg. Patients will be monitored for 90 days after their transplant to check how well the treatment works and to watch for any side effects. The study will look at whether patients develop severe COVID-19 symptoms, such as breathing difficulties or chest abnormalities visible on imaging tests.

The purpose of this research is to determine how well ibuzatrelvir works when used alone or combined with remdesivir in treating COVID-19 symptoms and reducing the amount of virus in people with weakened immune systems. The study includes people who have received organ transplants, those with blood cancers, individuals who have received certain cancer treatments, or those taking medications that affect their immune system.

During the study, participants will receive the study medication for up to three days. They will be monitored for changes in their COVID-19 symptoms and the amount of virus in their body. The study will track whether participants need emergency care, hospital treatment, or experience other health problems related to COVID-19. The total study period is 38 days, during which participants will have regular check-ups to monitor their health and any side effects.

The purpose of the study is to evaluate how well the immune system responds to these vaccines. Participants will receive different vaccine products, and their immune responses will be monitored over time. The study will look at the levels of antibodies, which are proteins made by the immune system to fight infections, and other immune responses in people who have received the vaccines. This includes those who have had different numbers of doses, those who received the vaccine at different intervals, and those who belong to various age groups or have different health conditions.

The study will take place over several years, with the aim of understanding how well these vaccines work against different variants of the virus. By the end of the study, researchers hope to gather valuable information on the effectiveness of these vaccines in providing protection against COVID-19.

The purpose of the study is to assess the safety and immune response of the PHH-1V81 booster in adults who have already received their initial COVID-19 vaccinations and at least one booster dose of an mRNA vaccine approved in the European Union. Participants will receive either the PHH-1V81 booster or the Comirnaty Omicron XBB.1.5 vaccine. The study will compare how well each vaccine works in boosting the immune system’s ability to fight the virus, particularly against the Omicron XBB.1.16 variant.

Throughout the study, participants will be monitored for any reactions or side effects after receiving the booster. The study will also measure the level of antibodies, which are proteins the body makes to fight infections, to see how well the vaccines work. The trial will help determine if the new PHH-1V81 vaccine is as effective as the existing Comirnaty vaccine in boosting immunity against COVID-19.

The purpose of the study is to assess the level of antibodies, which are proteins in the blood that help fight infections, against the most common variant of the virus. This will be done three times a year. The study will also look at how well the vaccines work in creating a strong immune response, which includes both the quality of the antibody response and the cellular immune response, which involves other parts of the immune system that help protect against infections.

Participants in the study will receive the vaccines through an injection. The study will take place over several years, from 2023 to 2026, to gather comprehensive data on how the immune system responds over time. This information will help improve understanding of vaccine effectiveness in people with different health conditions and contribute to better protection strategies against COVID-19.

The purpose of the study is to evaluate how the body’s natural defense system, known as the innate immune response, reacts shortly after receiving the Comirnaty JN.1 vaccine. Participants will receive the vaccine through an injection into the muscle. The study will observe the body’s response at different times: before the vaccine is given, and then 6 hours and 24 hours after the injection. Researchers will look at certain markers in the blood that indicate how the immune system is responding.

Throughout the study, researchers will also monitor for any serious side effects that might be related to the vaccine. The study aims to provide more information on how the vaccine affects the immune system in the short term, which can help in understanding its overall effectiveness and safety. The study is expected to conclude by February 2025.

The purpose of the study is to compare the immune response generated by the BIMERVAX booster in adolescents with the response seen in young adults aged 18 to 25 years. Participants will receive a single booster dose of BIMERVAX, and their immune response will be measured at the start of the study and again 14 days after receiving the booster. The study will also monitor any side effects or reactions to the vaccine, both immediately after vaccination and over a longer period.

Throughout the study, researchers will keep track of any local or systemic reactions, such as redness or swelling at the injection site, as well as any other adverse events that may occur. The study is designed to ensure the safety and tolerability of the BIMERVAX vaccine in adolescents, providing valuable information on its effectiveness as a booster for preventing COVID-19 in this age group.

The purpose of the study is to understand how well the immune system responds when these vaccines are given together. Participants will receive either the COVID-19 vaccine with the adjuvanted flu vaccine, the COVID-19 vaccine with the non-adjuvanted flu vaccine, or the COVID-19 vaccine alone. The study will involve several visits over a period of time, where participants will receive the vaccines and have their immune responses checked through blood tests.

Throughout the study, the safety of the vaccines will be closely monitored. Participants will be asked to report any side effects they experience, such as reactions at the injection site or other symptoms. The study aims to provide valuable information on the effectiveness and safety of these vaccines when given together, which could help improve vaccination strategies for older adults in the future.

Participants in the study will receive either the BIMERVAX vaccine, the Fluad Tetra vaccine, both vaccines together, or a placebo, which is a substance with no active ingredients. The vaccines are administered through an injection into the muscle. The study will monitor participants for any reactions or side effects for a period of time after the vaccination. This includes checking for any local reactions at the injection site, as well as any general reactions throughout the body.

The trial will also measure the levels of antibodies, which are proteins made by the immune system to fight infections, in the participants’ blood. This will help determine how well the vaccines work when given together. The study aims to provide valuable information on the safety and effectiveness of coadministering these vaccines in older adults, which could help guide future vaccination strategies.

The main purpose of this study is to evaluate the safety of different doses of the intranasal vaccine and compare how well both vaccines stimulate immune responses in the nose and bloodstream. The study is divided into two parts. In the first phase, researchers will test three different strengths of the nasal vaccine. In the second phase, they will compare the nasal vaccine to the injectable mRNA vaccine.

During the study, participants will receive one booster dose of either the nasal or injectable vaccine. They will be monitored for any side effects and will provide nose swabs and blood samples to measure their immune response. The monitoring period will continue for one year after vaccination. Researchers will also track whether participants develop SARS-CoV-2 infections during this time.

The purpose of this research is to determine how well ibuzatrelvir works compared to placebo in treating people with COVID-19 who are at high risk of their condition becoming worse. The study will include both adults and adolescents who weigh at least 40 kilograms (about 88 pounds) and who cannot or choose not to take other available COVID-19 treatments.

During the study, participants will take either ibuzatrelvir tablets or placebo tablets. The researchers will monitor participants for 28 days to see if they need emergency care, require oxygen support, need additional treatments, are hospitalized, or experience other health issues. They will also track how quickly symptoms improve and check for any lasting effects of COVID-19 for up to 24 weeks after treatment begins.

The purpose of this study is to see if the treatment can help improve breathing in patients who are experiencing severe respiratory failure, which means their lungs are not working well enough to get oxygen into the blood. The study will involve patients who are hospitalized with pneumonia caused by SARS-CoV-2 (the virus responsible for COVID-19) or other similar infections. The trial will last for a short period, with the treatment being given over a maximum of seven days.

Throughout the study, researchers will monitor the patients’ breathing and other health indicators to see if there is an improvement. They will also check how well patients tolerate the treatment and if there are any side effects. The goal is to find out if this new treatment can be a helpful addition to the current care for people with severe lung infections. The study is expected to continue until mid-2025.

The purpose of this study is to understand how these treatments affect the virus in the body, including how the virus changes and how the body responds to the treatment. The study will also look at how these treatments can prevent COVID-19. Participants will receive one of the treatments or a placebo, and their health will be monitored to see how the virus behaves during and after treatment. This includes checking for any changes in the virus, such as mutations, and observing the body’s immune response.

The study will create a biobank, which is a collection of biological samples, to help answer future questions about the use of these treatments compared to new COVID-19 treatments that are being developed. The study will take place over a period of time, and participants will be closely monitored to gather important information about the effectiveness and safety of these treatments.

The purpose of the study is to understand how these treatments affect the physical health-related quality of life in people with PASC. Participants in the study will receive either Metformin, Colchicine, or a placebo. The study will last for a total of 12 weeks, during which participants will take the medication in tablet form by mouth. The trial will monitor the participants’ health and any changes in their symptoms throughout this period.

At the end of the 12 weeks, the study will assess the impact of the treatments on various aspects of health, including physical function, fatigue, and mental health. The goal is to determine if these medications can help improve the quality of life for those experiencing ongoing symptoms after a COVID-19 infection. The study will also look at how well participants adhere to the treatment plan and any side effects they may experience.

The purpose of this study is to understand how Baricitinib behaves in the body of pediatric patients, which includes children from 1 year to less than 18 years old. The study will look at how the medication is absorbed, distributed, and eliminated by the body. This information is important to ensure the safety and effectiveness of the treatment in young patients who are receiving oxygen therapy due to their COVID-19 infection.

During the study, participants will receive Baricitinib for a period of up to 14 days. Researchers will monitor the children closely to gather information about the medication’s safety and how it moves through the body. This will help determine the best way to use Baricitinib in treating children with COVID-19 in the future.

Participants in the study will receive a single dose of the treatment through an intravenous infusion, which means it is given directly into a vein. Some participants will receive a placebo instead of the actual treatment. The study will compare the health status of participants after seven days to see if the treatment helps improve their condition. The study will also look at how the treatment affects the need for hospitalization and the overall health of participants over a period of 28 days.

The goal is to determine if the Anti-COVID-19 Hyperimmune Globulin (Human) can help reduce the severity of COVID-19 symptoms and prevent the disease from getting worse. The study will include participants who are at higher risk due to age or other health conditions. By testing this treatment, researchers hope to find a new way to help people recover from COVID-19 more quickly and with fewer complications.

Participants in the study will take the medication for a short period, up to five days. The study will monitor how the body processes the medication and check for any side effects. The study will also look at how well the medication works in reducing the risk of severe illness from COVID-19. Children from birth to under 18 years old who have tested positive for COVID-19 and show symptoms can be part of this study.

The study will collect information on the safety of the medication and how it affects the virus in the body. It will also assess how easy and pleasant it is for children to take the medication, which comes in the form of tablets or oral powder. The goal is to find a treatment that can help prevent severe COVID-19 in children who are at higher risk due to underlying health conditions.

The treatment involves taking tablets of nirmatrelvir and ritonavir by mouth for up to 5 days. Some participants will receive the actual medications, while others will receive a placebo. This approach helps determine if the treatment is effective in preventing the development of lasting symptoms.

The study will monitor participants’ symptoms and overall health for several months after treatment. This includes tracking any new symptoms that might develop, checking for additional infections, and evaluating the general safety of the medications. The research aims to understand if early treatment with these antiviral medications can prevent the development of long-term COVID-19 complications.

The purpose of the study is to determine if early administration of ORENCIA can improve the clinical recovery of patients with COVID-19 over a period of 60 days. Participants in the study will receive either the medication or a placebo shortly after being hospitalized. The trial will monitor their recovery process, focusing on how quickly they recover and their overall health status during the study period.

The study will track several outcomes, including the time it takes for patients to recover, their survival rate, and any need for additional medical support like mechanical ventilation. Safety will also be closely monitored by observing any serious side effects or adverse events that may occur during the trial. The goal is to gather information that could help improve treatment strategies for patients with COVID-19 in the future.

Participants in the study will take the medication orally, which means it is swallowed. The study will monitor the participants over a period of time to observe any side effects and how well the medication is tolerated. The study will also look at how the medication affects the symptoms of COVID-19 and whether it helps in reducing the virus in the body. The study will not use a placebo, meaning all participants will receive the actual medication.

The trial will include children and adolescents under 18 years of age who have been diagnosed with COVID-19. The study will track the participants’ health and any changes in their condition, including the need for additional medical support, over a period of up to 35 days. The goal is to gather information that could help in understanding how Obeldesivir works in treating COVID-19 in younger patients.

Participants in the study will receive either the combination of pamapimod and pioglitazone or a placebo. Pamapimod is an anti-inflammatory medication, while pioglitazone is known for its anti-inflammatory and antidiabetic properties. The study will last for four weeks, during which participants will take the medications orally in tablet form. The goal is to observe the number of days participants experience mild symptoms and to assess their overall recovery over the 28-day period.

The study will also monitor the safety and tolerability of the medication combination, as well as any potential side effects. Researchers will evaluate the time it takes for participants to recover based on their daily reports of symptoms. Additionally, the study will track any unplanned hospital admissions or deaths related to COVID-19 during the trial period. The results will help determine if this combination of medications can effectively aid in the recovery from COVID-19.

The purpose of the study is to determine if using a combination of these two medications or extending the duration of Paxlovid treatment from 5 to 10 days can help reduce the presence of the virus in the body. Participants will be randomly assigned to different treatment groups, and some may receive a placebo. The study will monitor the virus levels in participants’ nasal swabs over a period of time to see how well the treatments work.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. The study aims to provide valuable information on how to best treat COVID-19 in people with compromised immune systems, potentially leading to improved care and outcomes for this vulnerable group.

The purpose of the study is to evaluate how effective these treatments are in helping patients recover more quickly from COVID-19. Participants in the study will be monitored over a period of time to see how their symptoms change and how long it takes for them to feel fully recovered. The study will also look at other important factors, such as whether patients need to be admitted to the hospital or require additional medical care.

Throughout the study, participants will be asked to keep a daily diary to record their recovery progress. This will help researchers understand the impact of the treatments on the patients’ health and quality of life. The study aims to provide valuable insights into how to better manage COVID-19 in the community, especially for those who are more vulnerable to severe outcomes.

The purpose of this study is to determine if a 5-day treatment with S-217622 can improve the clinical outcomes for patients hospitalized with COVID-19. The study will involve patients who are admitted to the hospital with symptoms of a respiratory infection and have confirmed COVID-19. The trial will monitor participants over a period of 60 days to assess their recovery and overall health status. The main focus will be on how quickly patients recover, as well as their health condition at the end of the study period.

Throughout the study, researchers will also keep track of any serious health events or side effects that may occur. This will help ensure the safety of the participants and provide valuable information about the potential benefits and risks of using S-217622 as a treatment for COVID-19. The trial aims to provide insights into whether this new medication can be an effective addition to the current treatment options for hospitalized patients with COVID-19.

The purpose of the study is to investigate whether replacing mycophenolate mofetil with everolimus in kidney transplant patients leads to a better immune response to the COVID-19 vaccine. Participants in the study will receive either mycophenolate mofetil or everolimus and will be monitored for their immune response to the vaccines. The study will also look at the levels of antibodies, which are proteins the body makes to fight infections, after vaccination. Additionally, the study will monitor for any side effects or complications that may occur during the trial period.

Participants will be involved in the study for a period of up to 18 months. During this time, they will receive vaccinations and have regular check-ups to assess their health and immune response. The study will also track any changes in kidney function and the occurrence of any adverse events, which are unwanted effects that may happen during the study. The goal is to determine if everolimus can provide a stronger vaccine response while maintaining the health and safety of kidney transplant patients.

The purpose of the study is to see if these treatments can help improve the physical abilities and overall health of individuals with PACS. Participants will be randomly assigned to different groups, where they will receive either the lifestyle changes alone or in combination with one of the medications. The study will last for about three years, during which participants will be monitored to assess changes in their physical performance and immune function. The study will also look at the quality of life and any potential side effects of the treatments.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include measuring physical performance using a tool called the Short Physical Performance Battery, which evaluates balance, walking speed, and leg strength. The study will also examine changes in blood cells and inflammation levels to understand how the treatments might affect the immune system. By the end of the study, researchers hope to gain valuable insights into how these interventions can help people with PACS regain their strength and improve their overall well-being.

The study will involve taking the medication in the form of tablets by mouth for a period of up to five days. Participants will be monitored for any changes in their health, including any potential side effects or complications related to COVID-19. The study will track the number of participants who are hospitalized or who die from any cause within 29 days of starting the treatment. Additionally, the study will look at other outcomes, such as the occurrence of COVID-19-related complications and the need for medical visits due to the virus.

By participating in this study, researchers hope to gather important information about the potential benefits of Bemnifosbuvir Hemisulfate in treating high-risk patients with COVID-19. This information could help in developing effective treatments for those who are most vulnerable to severe outcomes from the virus. The study is designed to ensure the safety and well-being of all participants while providing valuable insights into the treatment of COVID-19.

The condition being studied is detected through special heart imaging called Cardiovascular Magnetic Resonance imaging, which can show inflammation in the heart tissue. The treatment involves taking tablets of prednisolone and losartan by mouth for 16 weeks. Some participants will receive the actual medications, while others will receive placebo tablets that look the same but contain no active medication.

The study will measure how well the heart functions before and after treatment using detailed heart imaging. This will help determine if the combination of medications can reduce heart inflammation and improve heart function in people who have developed heart problems after COVID-19 infection. The treatment’s safety will also be monitored throughout the study period.

Participants in the study will receive cysteamine in the form of hard capsules, taken orally. The study will monitor patients over a period of time to observe any side effects and to assess how the medication interacts with the body. The trial will also track the number of days it takes for patients to recover and be discharged from the hospital. The goal is to determine if cysteamine can be a safe and effective addition to the current treatment options for COVID-19 pneumonia.

Throughout the study, various health indicators will be measured, such as blood markers and the presence of the virus in the body. The trial will also look at how cysteamine affects the expression of certain genes related to the immune response. By the end of the study, researchers hope to gather valuable information on the potential benefits of cysteamine for patients with COVID-19 pneumonia.